Market Overview
According to fortune business insights, the global clinical trial supplies market size was valued at USD 5.45 billion in 2025. The market is projected to grow from USD 5.83 billion in 2026 to USD 11.80 billion by 2034, exhibiting a CAGR of 9.2% during the forecast period. North America dominated the clinical trial supplies market with a market share of 38.16% in 2025.
The analysis shows that a growing number of clinical trials, increasing R&D investment by pharmaceutical and biotech companies, and the expansion of hybrid and decentralized trials are driving market growth. The rapid development of biologics, biosimilars, and cell and gene therapies further boosts demand for specialized supply chain management. For instance, according to 2025 WHO statistics, approximately 162,704 clinical trials were conducted in China, indicating robust research activity.
Major Players Profiled in the Market Report:
- Thermo Fisher Scientific Inc. (U.S.)
- Parexel International (MA) Corporation (U.S.)
- Catalent Inc. (U.S.)
- Almac Group (U.K.)
- PCI Pharma Services (U.S.)
- Clinigen Limited (U.K.)
- Myonex (U.S.)
- Biocair (U.K.)
- Oximio (U.K.)
- KLIFO (Denmark)
Segments
Increasing Outsourcing to Propel Services Segment Growth
Based on type, the market is divided into products (investigational medicinal products, comparator drugs, ancillary supplies) and services (manufacturing, packaging, storage & distribution). The services segment holds the largest share, driven by increasing outsourcing of complex logistics, including planning, cold-chain distribution, and Direct-To-Patient (DTP) delivery.
High Volume of Trials to Drive Phase III Segment Expansion
By phase, the market is segmented into Phase I, II, III, and IV. The Phase III segment dominates with a 51.4% share in 2025, attributed to the large scale and complexity of these trials, which require extensive supplies and logistics management.
Manufacturing Advantages to Boost Small Molecules Segment
Based on modality, the market is categorized into small molecules, biologics, medical devices, and others. The small molecules segment leads with a 44.1% share in 2025, supported by easier manufacturing, formulation, and a high number of drug approvals.
Rising Cancer Prevalence to Drive Oncology Segment
By therapeutic area, the market is divided into oncology, infectious diseases, neurology, cardiology, and others. The oncology segment holds the largest share (projected 40.9% in 2026) due to the high prevalence of cancer and the vast number of ongoing oncology clinical trials.
High Trial Volume to Drive Pharmaceutical & Biotechnological Companies Segment
Based on end-user, the market is segmented into pharmaceutical & biotechnological companies, medical device companies, CROs, and others. Pharmaceutical & biotechnological companies dominate, holding a projected 59.0% share in 2026, as they are the primary sponsors of clinical trials.
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
For detailed market insights: https://www.fortunebusinessinsights.com/clinical-trial-supplies-market-111707
Report Coverage
The report offers:
- Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
- Comprehensive insights into regional developments.
- A list of major industry players and their profiles.
- Key strategies adopted by the market players, including acquisitions and partnerships.
- The latest industry developments and market trends.
Drivers & Restraints
Increasing Number of Clinical Trials to Propel Market Growth
The continuous increase in the number of clinical trials worldwide is the primary driver for the market. This surge escalates the demand for reliable supply planning, packaging, labeling, temperature-controlled logistics, and overall supply chain management. According to 2026 data from NCBI, over 583,905 clinical trial studies were registered globally.
However, the high cost associated with clinical trial supply management may restrain market growth. The complexity of modern trials, especially those involving personalized medicine, increases expenses related to specialized manufacturing, comparator sourcing, and cold-chain logistics. Inefficient forecasting can also lead to overproduction and waste, with the pharmaceutical sector losing an estimated USD 20.0 billion to USD 35.0 billion annually from temperature-related spoilage.
Regional Insights
High Volume of Trials Propels Market Growth in North America
North America holds the dominant market share, valued at USD 2.08 billion in 2025. The region's leadership is driven by a high concentration of pharmaceutical and biotech companies, substantial R&D investment, and a large number of ongoing clinical trials. The U.S. market alone is estimated to be approximately USD 1.99 billion in 2026.
Europe is the second-largest market, projected to reach USD 1.79 billion in 2026, supported by a robust clinical research infrastructure and an increasing number of trials.
Asia Pacific is a rapidly growing region, projected to reach USD 1.30 billion in 2026. Growth is fueled by rising healthcare expenditure, improving research infrastructure, and a large patient pool, particularly in China and India.
Clinical Trial Supplies Market Trends
A key trend is the increasing adoption of digital and automation technologies. Integrated digital solutions like Randomization and Trial Supply Management (RTSM), electronic data capture (EDC), and real-time temperature monitoring are enhancing trial visibility, automating resupply decisions, and reducing waste. These technologies also enable more patient-centric supply models, such as home delivery and remote dispensing. A 2024 survey indicated that 98% of studies utilized multiple clinical trial technologies.
Competitive Landscape
Strategic Acquisitions and Service Expansion to Strengthen Market Position
The market is led by key players such as Thermo Fisher Scientific Inc. and Parexel International (MA) Corporation. These companies maintain their dominance through a strong service portfolio and strategic inorganic growth, including acquisitions and mergers. For example, in October 2025, Thermo Fisher Scientific Inc. acquired Clario Holdings, Inc. to enhance its clinical trial data solutions. Other companies like Catalent Inc. are focusing on expanding their service channels to strengthen their market presence.
Key Industry Developments
- April 2026: PCI Pharma Services expanded its sterile fill-finish and advanced drug delivery capabilities in the U.S.
- April 2026: Suvoda launched its next-generation "agentic RTSM," which uses AI to accelerate study setup.
- September 2025: Clinigen acquired SSI Strategy, a strategic consulting firm, to create a comprehensive global partner for the biopharma industry.
- August 2025: Biocair expanded its operations in the Asia Pacific region by opening a new office in Shanghai, China.
- December 2024: KLIFO strengthened its brand presence by launching a new state-of-the-art clinical trial supply facility near Copenhagen.
What’s Driving Japan’s Market? Discover the Latest Clinical Trial Supplies Market Insights
Comments